TriLink BioTechnologies® & Alphazyme Collaborate to Launch New CleanScribe™ RNA Polymerase
TriLink BioTechnologies and Alphazyme, both part of Maravai LifeSciences (MRVI), have collaborated to launch CleanScribe™ RNA Polymerase, a novel enzyme that reduces double-stranded RNA (dsRNA) in mRNA production by up to 85%. This innovation helps develop safer, more potent mRNA therapeutics without compromising mRNA yield, capping efficiency, or integrity.
CleanScribe RNA Polymerase catalyzes the in vitro transcription (IVT) of recombinant genes regulated by the T7 promoter, significantly reducing dsRNA formation compared to wild-type T7 RNA Polymerase. The product is ideal for mRNA synthesis, saRNA synthesis, radiolabeled RNA probe preparation, and RNA construct development.
TriLink also offers mRNA capping analogs, raw materials, advanced scale-up capabilities, and expertise in mRNA, oligonucleotide, and enzyme production. With over 25 years of nucleic acid experience, TriLink provides high-quality technology, chemistry, and CDMO services for advancing therapeutics, vaccines, and diagnostics.
TriLink BioTechnologies e Alphazyme, entrambe parte di Maravai LifeSciences (MRVI), hanno collaborato per lanciare CleanScribe™ RNA Polymerase, un nuovo enzima che riduce il RNA a doppia catena (dsRNA) nella produzione di mRNA fino al 85%. Questa innovazione aiuta a sviluppare terapeutiche mRNA più sicure e potenti senza compromettere il rendimento dell'mRNA, l'efficienza di capping o l'integrità.
CleanScribe RNA Polymerase catalizza la trascrizione in vitro (IVT) di geni ricombinanti regolati dal promotore T7, riducendo significativamente la formazione di dsRNA rispetto alla wild-type T7 RNA Polymerase. Il prodotto è ideale per la sintesi di mRNA, la sintesi di saRNA, la preparazione di sonde RNA radiomarcate e lo sviluppo di costrutti RNA.
TriLink offre anche analoghi di capping di mRNA, materie prime, capacità avanzate di scale-up e competenze nella produzione di mRNA, oligonucleotidi e enzimi. Con oltre 25 anni di esperienza in acidi nucleici, TriLink fornisce tecnologia di alta qualità, chimica e servizi CDMO per l'avanzamento di terapeutiche, vaccini e diagnostici.
TriLink BioTechnologies y Alphazyme, ambas partes de Maravai LifeSciences (MRVI), han colaborado para lanzar CleanScribe™ RNA Polymerase, una nueva enzima que reduce el ARN de doble cadena (dsRNA) en la producción de mRNA hasta en un 85%. Esta innovación ayuda a desarrollar terapias de mRNA más seguras y potentes sin comprometer el rendimiento, la eficiencia de capping o la integridad del mRNA.
CleanScribe RNA Polymerase cataliza la transcripción in vitro (IVT) de genes recombinantes regulados por el promotor T7, reduciendo significativamente la formación de dsRNA en comparación con la wild-type T7 RNA Polymerase. El producto es ideal para la síntesis de mRNA, la síntesis de saRNA, la preparación de sondas de ARN radiomarcadas y el desarrollo de constructos de ARN.
TriLink también ofrece análogos de capping de mRNA, materias primas, capacidades avanzadas de escalado y experiencia en la producción de mRNA, oligonucleótidos y enzimas. Con más de 25 años de experiencia en ácidos nucleicos, TriLink proporciona tecnología de alta calidad, química y servicios CDMO para avanzar en terapias, vacunas y diagnósticos.
TriLink BioTechnologies와 Alphazyme은 Maravai LifeSciences (MRVI)의 일원으로서 CleanScribe™ RNA Polymerase를 출시하기 위해 협력했습니다. 이 새로운 효소는 mRNA 생산에서 이중 가닥 RNA(dsRNA)를 최대 85%까지 줄입니다. 이 혁신은 mRNA 수확량, 캡핑 효율성 또는 무결성을 손상시키지 않으면서 더 안전하고 강력한 mRNA 치료제를 개발하는 데 도움을 줍니다.
CleanScribe RNA Polymerase는 T7 프로모터에 의해 조절되는 재조합 유전자의 인 비트로 전사(IVT)를 촉매하여 야생형 T7 RNA Polymerase와 비교하여 dsRNA 형성을 상당히 줄입니다. 이 제품은 mRNA 합성, saRNA 합성, 방사선 표지 RNA 프로브 준비 및 RNA 구조물 개발에 적합합니다.
TriLink는 또한 mRNA 캡핑 유사체, 원자재, 고급 스케일업 기능 및 mRNA, 올리고뉴클레오타이드 및 효소 생산에 대한 전문성을 제공합니다. 25년 이상의 핵산 경험을 바탕으로 TriLink는 치료제, 백신 및 진단을 발전시키기 위한 고품질 기술, 화학 및 CDMO 서비스를 제공합니다.
TriLink BioTechnologies et Alphazyme, faisant toutes deux partie de Maravai LifeSciences (MRVI), ont collaboré pour lancer CleanScribe™ RNA Polymerase, une enzyme novatrice qui réduit l'ARN double brin (dsRNA) dans la production de mRNA jusqu'à 85%. Cette innovation aide à développer des thérapeutiques mRNA plus sûres et plus puissantes sans compromettre le rendement en mRNA, l'efficacité du capuchon ou l'intégrité.
CleanScribe RNA Polymerase catalyse la transcription in vitro (IVT) de gènes recombinants régulés par le promoteur T7, réduisant considérablement la formation de dsRNA par rapport à la T7 RNA Polymerase de type sauvage. Le produit est idéal pour la synthèse de mRNA, la synthèse de saRNA, la préparation de sondes RNA radiomarquées et le développement de constructions RNA.
TriLink propose également des analogues de capage mRNA, des matières premières, des capacités avancées de mise à l'échelle et une expertise dans la production de mRNA, d'oligonucléotides et d'enzymes. Avec plus de 25 ans d'expérience dans les acides nucléiques, TriLink fournit des technologies de haute qualité, de la chimie et des services CDMO pour faire avancer les thérapeutiques, les vaccins et les diagnostics.
TriLink BioTechnologies und Alphazyme, beide Teil von Maravai LifeSciences (MRVI), haben zusammen CleanScribe™ RNA Polymerase veröffentlicht, ein neuartiges Enzym, das die Bildung von doppelsträngiger RNA (dsRNA) in der mRNA-Produktion um bis zu 85% reduziert. Diese Innovation unterstützt die Entwicklung sicherer und potenterer mRNA-Therapeutika, ohne die mRNA-Ausbeute, die Kapselfähigkeit oder die Integrität zu beeinträchtigen.
CleanScribe RNA Polymerase katalysiert die in vitro Transkription (IVT) von rekombinanten Genen, die durch den T7-Promotor reguliert werden, und verringert die Bildung von dsRNA im Vergleich zur Wildtyp T7 RNA Polymerase erheblich. Das Produkt ist ideal für die mRNA-Synthese, die saRNA-Synthese, die Vorbereitung von radioaktiv markierten RNA-Sonden und die Entwicklung von RNA-Konstrukten.
TriLink bietet auch mRNA-Capping-Analoga, Rohstoffe, fortschrittliche Hochskalierungsfähigkeiten und Fachwissen in der Produktion von mRNA, Oligonukleotiden und Enzymen an. Mit über 25 Jahren Erfahrung mit Nukleinsäuren bietet TriLink hochwertige Technologie, Chemie und CDMO-Dienstleistungen zur Weiterentwicklung von Therapeutika, Impfstoffen und Diagnostika.
- Launch of CleanScribe™ RNA Polymerase, reducing dsRNA formation by up to 85% in mRNA production
- Potential for developing safer and more potent mRNA therapeutics
- No compromise on mRNA yield, capping efficiency, or integrity
- Easy integration into existing IVT protocols without extensive optimization
- Expansion of TriLink's product portfolio in the mRNA production field
- None.
Drug developers & researchers can now leverage the CleanScribe enzyme to reduce dsRNA formation by up to
CleanScribe RNA Polymerase is a novel DNA-dependent RNA polymerase that catalyzes the in vitro transcription (IVT) of a recombinant gene regulated by the T7 promoter. During the IVT reaction, dsRNA can be produced as a byproduct, which can trigger undesirable inflammatory responses in host cells. The CleanScribe enzyme drastically reduces dsRNA formation during IVT by up to
“In this era of mRNA-based medicine, drug developers must streamline their supply chain to remain agile and keep up with demand,” said Justin Barbosa, VP and General Manager of TriLink Discovery. “The integration of high-performing IVT enzymes, mRNA capping analogs, and modified nucleotides are must-haves in mRNA manufacturing.”
CleanScribe RNA Polymerase provides researchers with a simple way to significantly reduce dsRNA in their IVT without compromising other important mRNA quality attributes. The product’s robustness, reproducibility, and dsRNA reduction make it ideal for mRNA synthesis, saRNA synthesis, radiolabeled RNA probe preparation, and RNA construct development for additional studies. It is also straightforward for researchers to integrate the enzyme into their IVT protocols without requiring extensive optimization.
“We’re thrilled to have had the opportunity to work with TriLink on the launch of CleanScribe RNA Polymerase,” shared Chad Decker, VP and General Manager at Alphazyme. “You can’t produce high-quality mRNA-based therapeutics without high-quality raw material, which is why the potential impact of this IVT enzyme on the field is so exciting.”
In addition to its newly launched CleanScribe RNA Polymerase, TriLink offers mRNA capping analogs (including the award-winning CleanCap® M6), mRNA raw materials (nucleotides and other IVT enzymes including wild-type T7 RNA polymerase), advanced scale-up capabilities, and unrivaled expertise in mRNA, oligonucleotide, and enzyme production. Leveraging more than 25 years of nucleic acid experience, TriLink is dedicated to advancing therapeutics, vaccines, and diagnostics by providing its customers with high-quality technology and chemistry and Contract Development and Manufacturing Organization (CDMO) services.
To learn more about TriLink’s products and services, visit trilinkbiotech.com.
About TriLink BioTechnologies
TriLink BioTechnologies, a Maravai LifeSciences company, is a global leader in nucleic acid and mRNA solutions. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors, and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed, to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders, to enabling future pandemic response plans. For more information, visit trilinkbiotech.com.
About Alphazyme
Alphazyme LLC, a Maravai LifeSciences company, was founded by enzyme development and production experts with a track record of success and a mission to be the world's premier partner for custom molecular biology enzymes produced at industrial scale. Alphazyme collaborates with the manufacturers of nucleic acid synthesis and detection platforms to produce affordable enzymes of the highest quality that meet the requirements of the growing markets for custom DNA and RNA molecules, genomic medicines and genetic analysis. Our team values collaboration, customer success and continuous improvement. Learn more about Alphazyme at alpha-zyme.com.
About Maravai LifeSciences
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.
For more information about Maravai LifeSciences, visit www.maravai.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240924933319/en/
Investor Contact:
Deb Hart
Maravai LifeSciences
+ 1 858-988-5917
ir@maravai.com
Media Contact:
Liz Robinson of CG Life
TriLink BioTechnologies
+1 312-997-2436
lrobinson@cglife.com
Source: TriLink BioTechnologies
FAQ
What is CleanScribe™ RNA Polymerase and how does it benefit mRNA production for MRVI?
How does CleanScribe™ RNA Polymerase compare to wild-type T7 RNA Polymerase for MRVI's mRNA production?
What applications can CleanScribe™ RNA Polymerase be used for in MRVI's product lineup?
How does the launch of CleanScribe™ RNA Polymerase impact MRVI's position in the mRNA therapeutics market?
